Objective-Tissue macrophages induce and perpetuate proinflammatory responses, thereby promoting metabolic and cardiovascular disease. Lipoprotein lipase (LpL), the rate-limiting enzyme in blood triglyceride catabolism, is expressed by macrophages in atherosclerotic plaques. We questioned whether LpL, which is also expressed in the bone marrow (BM), affects circulating white blood cells and BM proliferation and modulates macrophage retention within the artery. Approach and Results-We characterized blood and tissue leukocytes and inflammatory molecules in transgenic LpL knockout mice rescued from lethal hypertriglyceridemia within 18 hours of life by muscle-specific LpL expression (MCKL0 mice). LpL-deficient mice had ≈40% reduction in blood white blood cell, neutrophils, and total and inflammatory monocytes (Ly6C/G hi ). LpL deficiency also significantly decreased expression of BM macrophage-associated markers (F4/80 and TNF-α [tumor necrosis factor α]), master transcription factors (PU.1 and C/EBPα), and colony-stimulating factors (CSFs) and their receptors, which are required for monocyte and monocyte precursor proliferation and differentiation. As a result, differentiation of macrophages from BM-derived monocyte progenitors and monocytes was decreased in MCKL0 mice. Furthermore, although LpL deficiency was associated with reduced BM uptake and accumulation of triglyceriderich particles and macrophage CSF-macrophage CSF receptor binding, triglyceride lipolysis products (eg, linoleic acid) stimulated expression of macrophage CSF and macrophage CSF receptor in BM-derived macrophage precursor cells. Arterial macrophage numbers decreased after heparin-mediated LpL cell dissociation and by genetic knockout of arterial LpL. Reconstitution of LpL-expressing BM replenished aortic macrophage density. Conclusions-LpL regulates peripheral leukocyte levels and affects BM monocyte progenitor differentiation and aortic macrophage accumulation.
A lthough inflammation primarily serves to ameliorate injury or infection, tissue macrophage-mediated inflammatory responses promote atherosclerotic cardiovascular disease (CVD) and metabolic disorders. Accumulation of lipoproteins, especially low-density lipoprotein (LDL), in the aortic wall leads to an inflammatory cascade that attracts blood leukocytes and traps monocytes in the subendothelial space. 1 Infiltrated monocytes can differentiate to macrophages that phagocytose accumulated LDL and become foam cells, which contribute to fatty streaks that precede atherosclerotic plaque formation. 2 High white blood cell (WBC) levels thus directly accelerate atherosclerotic CVD 3, 4 and are also associated with obesity and type 2 diabetes mellitus, which also increase risk of CVD. [5] [6] [7] Furthermore, hypercholesterolemia in mice promotes blood leukocytosis, increases in inflammatory monocyte (Ly6C hi ) levels, and macrophage infiltration to enhance progression of atherosclerotic lesions. 8 Tissue macrophages robustly express lipoprotein lipase (LpL), the rate-limiting enzyme in circulating triglyceride metabolism. Macrophages within atherosclerotic lesions are a major site of LpL expression. 9, 10 Loss-of-function studies show that macrophage-derived LpL increases atherosclerosis, [11] [12] [13] suggesting a direct role of LpL levels in mediating atherosclerotic lesion development. In our previous studies, aortic LpL levels in nonhypercholesterolemic mice positively correlated with aortic wall macrophage levels. 14, 15 Several mechanisms by which LpL may promote atherosclerosis have been proposed: (1) LpL acts as a nonenzymatic bridging molecule that anchors atherogenic lipoproteins to the extracellular matrix to promote lipoprotein retention [16] [17] [18] ; (2) LpL hydrolyzes lipoproteins to produce proatherogenic, cholesterol-rich LDL 1, 19 ; (3) LpL-mediated lipolysis products serve as energy substrates (fatty acids [FAs] ) that increase macrophage inflammatory responses 20 ; (4) LpL functions as a monocyte adhesion molecule [21] [22] [23] ; and (5) LpL induces proinflammatory TNF-α (tumor necrosis factor α) expression and production by macrophages. 24 Atherogenic actions of LpL might thus lead to a vicious cycle, whereby elevated macrophage levels increase LpL secretion, which promotes additional macrophage accumulation in the aortic wall. Recent genetic studies in humans have associated heterozygous LpL deficiency with early-onset coronary heart disease, 25 an effect that might reflect hypertriglyceridemia, increased postprandial lipemia, and low highdensity lipoprotein cholesterol levels. The systemic and local effects of LpL on atherogenesis are still not fully defined.
We hypothesized that expression of LpL by WBCs and their precursors alters the circulating levels of monocytes, as well as their entry into the aortic wall to promote atherosclerosis. We first tested this by examining whether LpL expression affects circulating WBC numbers and bone marrow (BM) myelopoiesis. Here, we show that LpL deficiency was associated with reduced circulating WBC and monocyte levels, reduced BM colony-stimulating factor (CSF) and CSF receptor (CSF-R) expression, and fewer macrophages in the aorta of high fat (HF)-fed mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

LpL Deficiency Alters Blood Leukocyte Profiling
To assess whether LpL expression modulates circulating WBC levels and subtypes, LpL-deficient mice (TmLpL0) were generated by crossing floxed LpL mice with β-actindriven tamoxifen-inducible Cre transgenic mice. 26 On a chow diet, total WBCs, monocytes, and percent monocytes/WBC (inset) were reduced in TmLpL0 mice compared with control floxed mice ( Figure 1A ). Because TmLpL0 mice are hypertriglyceridemic (≈400 mg/dL; n=10), we questioned whether the alteration in blood leukocyte levels was caused by elevated blood triglyceride levels rather than by LpL deficiency. Using an LpL deletion mouse model that expresses LpL only in skeletal muscle (to prevent neonatal death) and maintains normal cholesterol and triglyceride levels, 27 denoted as MCKL0 mice, 28 we determined that this effect is indeed attributable to LpL deficiency ( Figure 1B) . The reduction in the percentages of monocytes/WBC (inset) in MCKL0 mice is consistent and comparable with percent monocytes/WBC in TMLpL0 mice, 40±0.62% versus 36±1.81%, respectively (inset in Figure 1A and 1B). Other major leukocyte subsets, that is, neutrophils and lymphocytes, were reduced by 30% and 60%, respectively (n=12-15; P<0.05). We also observed a marked shift in the ratio of Ly6C/G hi (Gr-1 hi ) to Gr-1 lo monocytes that resemble human inflammatory classical and anti-inflammatory nonclassical monocytes, respectively, by flow cytometry. Compared with wild-type (Wt) mice, blood monocytes in MCKL0 mice had a significantly greater nonclassical to classical ratio ( Figure 1C and 1D) comprising a smaller percentage of total WBCs ( Figure 1D , inset). Both Wt and MCKL0 mice showed no signs of active inflammatory responses.
LpL Deletion Modulates Expression of Growth Factors Required for BM Hematopoiesis and Myelopoiesis
We next studied whether changes in blood leukocyte profiling and decreases in total leukocytes in MCKL0 mice were associated with altered BM myelopoiesis. We observed decreased gene expression of macrophage-associated markers-F4/80, TNF-α, and mannose receptor-in unsorted BM cell homogenates of MCKL0 mice compared with Wt ( Figure 2A ). Expression of master regulatory transcription factors required for hematopoietic progenitor cell proliferation and differentiation, including PU.1 (P<0.05) and C/EBPα (P<0.05; Figure 2B ), was also reduced in BM of MCKL0 mice when compared with Wt mice. Reduced expression of PU.1 and C/ EBPα may be attributable to the reduction in BM total lineage negative (lin − ) stem and progenitor cells in MCKL0 mice when compared with Wt ( Figure IA and IB in the online-only Data Supplement). However, populations of BM progenitor cells at early hematopoietic branch points, including hematopoietic stem and progenitor cells, common myeloid progenitors, and granulocyte-macrophage progenitors, were not altered in MCKL0 compared with Wt mice ( Figure IC in the online-only Data Supplement).
These modifications in blood leukocyte profiling can also occur at the terminally differentiated stages of hematopoiesis. We thus examined whether LpL deficiency affects expression of growth factors that act on BM progenitor cells at lineage-committed stages, such as monocyte progenitors and monocytes. Strikingly, BM expression of all CSFs, including granulocyte CSF, granulocyte macrophage CSF (GM-CSF), and macrophage CSF (M-CSF; Figure 2C) Figure 2D ).
Alterations in M-CSF and M-CSF-R Expression Relate to LpL-Mediated Triglyceride Metabolism
BM expression of LpL is associated with triglyceride-rich lipoprotein catabolism, such as chylomicrons. 29 We questioned whether LpL-mediated reductions in CSF/CSF-R expression that contribute to altered BM myelopoiesis and WBC levels reflect changes in cellular triglyceride uptake. We speculated that LpL deficiency would reduce cellular triglyceride uptake and metabolism, which would alter the expression of essential growth factors for myeloid cell differentiation and proliferation. To test this, we treated differentiating macrophages derived from Wt and MCKL0 mouse BM with linoleic acid (LA)-rich triglyceride particles (soy oil-based lipid emulsion, Intralipid), a key pathway for delivering FAs to cells, labeled with [ 3 H]cholesteryl ether. 30 As previously measured by our laboratory, [30] [31] [32] we have established that triglyceride mass essentially equals triglyceride deposition because basal cellular triglyceride levels are low and cellular triglyceride synthesis is negligible during the 4-hour incubation (ie, <1% of triglyceride uptake). Our studies examining BM cell triglyceride metabolism show that cellular triglyceride uptake and accumulation were reduced by 22% and 50%, respectively, in the LpL-deficient cells ( Figure 3A ). The ratio of cellular triglyceride deposition to triglyceride uptake, which represents cellular triglyceride use, was reduced by ≈40% in BM-derived differentiating macrophages from MCKL0 mice compared with those in Wt mice ( Figure 3A) .
We also examined whether the addition of exogenous LpL can rescue the defective triglyceride uptake and metabolism. Addition of exogenous LpL increased triglyceride uptake in Wt BM-derived macrophage precursor cells that already have adequate expression of LpL. The addition of exogenous LpL to the LpL-deficient cells increased cellular triglyceride uptake, mass, and utilization to levels similar to that in Wt cells ( Figure 3A) .
We next examined whether exogenous LpL or triglyceridederived metabolites, such as LA, can modulate M-CSF/M-CSF-R expression in BM-derived monocyte or macrophage precursor (BMMP) cells from MCKL0 mice. Differentiating monocytes or monocyte precursors were treated with LpL, LA-rich triglyceride particles (Intralipid) in the presence of LpL and LA. The results show that the addition of exogenous LpL and triglyceride particles had a small effect on M-CSF expression but had no effect on M-CSF-R expression. LA stimulated expression of both M-CSF and M-CSF-R ( Figure 3B ; P<0.05) in MCKL0 BM-derived myeloid precursor cells. In Wt BMMP cells, although the addition of exogenous LpL alone had no effect on M-CSF and a small effect on M-CSF-R (P<0.05) expression, addition of triglyceride in the presence of LpL increased M-CSF-R expression (ns) with a lesser effect on M-CSF levels. LA stimulated expression of M-CSF ( Figure 3C ).
Because of earlier reports on the role of peroxisome proliferator-activated receptor γ (PPARγ) in influencing lipid metabolism and production of M-CSF, we questioned whether transcription of M-CSF is regulated by the PPARγ-mediated NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling cascade. Our data show a consistent inverse relationship between PPARγ and M-CSF in BMMP cells. Expression of M-CSF was downregulated while PPARγ was upregulated, in the untreated BMMP cells in MCKL0 mice when compared with Wt. Furthermore, when additional exogenous FA was supplied during BMMP differentiation, increases in M-CSF expression were associated with the suppression of PPARγ expression in both Wt and MCKL0 mice ( Figure 3D ).
LpL Deletion Attenuates BM-Derived Monocyte Differentiation to Macrophages
Because our data show that LpL deficiency reduced the expression of growth factors necessary for the differentiation of monocytes or monocyte precursor cells, we sought to directly assess whether the reduced expression of CSFs and CSF-Rs in BM or in local tissues modulates differentiation or proliferation of BM myeloid precursor cells. We isolated BM cells, including monocyte/macrophage precursors, from MCKL0 and Wt mice. There was no significant difference in total proliferated BM cells determined by hemocytometer (70-80×10 mature differentiated macrophages by flow cytometry revealed that monocyte differentiation to macrophages was decreased by ≈40% under the MCKL0 background ( Figure 4A and 4B). Thus, our findings ( Figures 3A, 3B , 4A, and 4B) suggest that LpL deficiency impairs monocyte/macrophage differentiation by causing reduced M-CSF/M-CSF-R expression and by attenuating cellular responsiveness to M-CSF.
LpL Promotes Binding of M-CSF to Its Receptor
We next sought to examine the potential mechanisms underlying the effects of LpL on modulating BM-derived macrophage precursor cellular responsiveness to M-CSF. Mammalian M-CSF is expressed as 3 subtypes-soluble glycoprotein, cell membrane-associated glycoprotein, and matrix-anchored proteoglycan-that differentially stimulate target cells expressing M-CSF-R. It has been suggested that the density of monocyte-differentiated macrophages at the particular sites is controlled by local synthesis of the membrane-associated M-CSF and selective sequestration of the secreted proteoglycan form of M-CSF. 33 When we assessed this effect in vivo by sorting differentiating BM myeloid precursor cells in MCKL0 and Wt mice, we observed fewer M-CSF + /M-CSF-R + cell populations in MCKL0 mice compared with Wt ( Figure 4C ). Potential interacting factors that may affect M-CSF and M-CSF-R cellular interaction were examined. These include heparin, an LpL cell dissociator, tetrahydrolipstatin, an LpL lipolytic activity inhibitor, and sodium chlorate (NaClO 3 ), a proteoglycan synthesis inhibitor. Our data show that tetrahydrolipstatin has no effects on M-CSF and M-CSF-R interaction, suggesting that the interaction of M-CSF and M-CSF-R is independent of LpL enzymatic activity (data not shown), and addition of heparin had no effects on cell association of M-CSF and M-CSF-R in BM (data not shown). However, cellular association of M-CSF and M-CSF-R was significantly reduced by NaClO 3 ( Figure 4D ), which supports the hypothesis that LpL plays a role in bridging BM M-CSF proteoglycan to cells to stimulate the maturation of monocyte precursor or monocytes. We thus propose that LpL modulates BM myelopoiesis by influencing M-CSF interaction with its receptor, which triggers a downstream signaling cascade to stimulate monocyte differentiation to macrophages.
Aortic Macrophage Levels Correspond to LpL Expression
LpL actions described above led us to investigate in vivo the effects of LpL deletion on monocyte homing and macrophage accumulation in the aortic wall. For these effects, we proposed that LpL would need to be present at the surface of cells. To test this hypothesis, we used heparin to dissociate LpL from cell surfaces. We examined whether LpL affects aortic monocyte or macrophage levels through its cell surface localization in the aortic lumen modulated by heparin. Wt mice were fed a chow or saturated HF diet for 12 weeks to increase arterial LpL levels as previously described. 34 Injection of heparin resulted in increased plasma-free FA levels ( Figure 5A ) and decreased plasma triglyceride levels in both chow and HF feeding groups ( Figure 5A ). Plasma cholesterol levels were increased by HF diet but were not affected by heparin ( Figure 5A ). Aorta sections were stained with specific fluorescent markers for LpL, macrophages, and endothelial cells. Consistent with our previous reports, 14, 34 aortic immunofluorescence of endothelial cells and smooth muscle cells was not altered by heparin treatment or HF feeding, suggesting that these cells remained intact in the artery and their proliferation is not altered by heparin or HF diet ( Figure II of macrophage-associated LpL is extracellular. Heparin treatment also led to a significant decrease in aortic macrophage number in HF-fed mice ( Figure 5C ), likely attributable to reduced LpL at cell surfaces, which would decrease macrophage levels in the aorta. This effect was rapid, manifesting by 10 minutes after heparin treatment, indicating that heparin treatment causes a rapid egress of these cells from the arterial wall.
To confirm that these changes in aortic macrophage levels were because of the presence of aortic LpL, we examined aortic macrophage density and distribution in MCKL0 mice. Levels of aortic macrophage immunofluorescence were visually low in both chow-fed Wt and MCKL0 mice ( Figure 6A) ; however, quantified macrophage levels were significantly reduced in MCKL0 mice when compared with Wt mice ( Figure 6B ). We next examined the role of LpL expressed specifically by macrophages in influencing aortic macrophage levels by comparing the number of aortic macrophages in MCKL0 mice transplanted with MCKL0 BM producing LpL-deficient macrophages (MCKL0→MCKL0) or Wt mouse BM producing LpL-expressing macrophages (Wt→MCKL0), as well as control Wt mice transplanted with Wt BM (Wt→Wt; control). Four weeks after transplantation, mice were placed on HF diets for 8 weeks. Although HF diets can increase MCKL0 mouse plasma cholesterol levels, their plasma triglyceride levels remained in the normal range. 27 In the aorta, as expected, HF diets increased macrophage levels in Wt mice transplanted with Wt BM (HF Wt→Wt) when compared with the chow-fed group (chow Wt→Wt) mice.
Aortic LpL deficiency (HF MCKL0→MCKL0) reduced macrophage accumulation by >40% when compared with HF Wt→Wt. Reconstitution of Wt BM into MCKL0 mice (HF Wt→MCKL0) significantly increased aortic macrophages (P<0.05), and the levels of LpL and macrophages were comparable to those in Wt mice ( Figure 6C ). Quantification of macrophages in different aortic layers shows that LpL deletion led to reduced macrophage counts primarily in the aortic media ( Figure 6D ). Aortic F4/80, CD/68, and chemoattractant MCP-1 (monocyte chemoattractant protein-1) mRNA levels were decreased in MCKL0→MCKL0 mice compared with Wt→MCKL0 (Table I in the online-only Data Supplement).
Therefore, our data in the aorta indicate that effects of LpL on blood monocyte levels and properties can contribute to modulations in immune cell responses in an important tissue involved in CVD, the artery.
Discussion
The role of LpL in vascular disease is unclear because macrophage-specific LpL deficiency reduces atherosclerotic CVD in animal models, but partial LpL deficiency in humans increases CVD risk. 11, 13, 25, 35 These data suggest that the role of macrophage-LpL in vascular pathology is cell specific. Indeed, we found that loss of LpL reduced the response of BM-derived macrophages to M-CSF. We went on to show that this is because of changes in both expression of M-CSF and in M-CSF interaction with monocyte and macrophage precursor cells. Aside from its action as a lipolytic enzyme, LpL has several anchoring functions that increase lipoprotein association with extracellular matrix 17 and attachment of cells to endothelial surfaces. 21 We now provide evidence for a new and unique action of LpL that captures and promotes M-CSF activities. In addition, while investigating the effects of loss of LpL in arteries with heparin, we discovered that heparin also reduces arterial macrophage content, likely by inhibiting LpL-mediated macrophage retention in the aortic wall.
Although LpL is highly expressed in BM, few studies have assessed the relationship between LpL and BM hematopoiesis or blood leukocyte parameters. Our findings indicate that transgenic (MCKL0) LpL loss-of-function mouse models are associated with substantial reductions in blood leukocytes and, specifically, monocytes. We found that LpL deficiency led to reduced expression of master regulatory transcription factors (PU.1 and C/EBPα) and growth factors (CSFs and CSF-Rs) critical for BM myeloid cell proliferation and differentiation. Although the total numbers of lineage negative progenitors cells were reduced in MCKL0 mice ( Figure IB in the online-only Data Supplement), the reduced myeloid cell differentiation was only observed at the later stage of hematopoiesis-monocyte progenitors to monocytes or monocytes to macrophages. Further studies are needed to investigate whether LpL deficiency also alters BM myeloid cell proliferation.
We suggest that the observed decreases in blood monocytes and tissue macrophages in MCKL0 mice result from lower levels of CSFs, such as M-CSF, which catalyze the differentiation of both monocyte progenitors and monocytes. M-CSF is produced in a variety of tissues with expression levels and functions depending on local microenvironmental stimuli. We suggest that the density of macrophages in particular tissues is controlled by local synthesis of membraneassociated M-CSF and selective sequestration of the secreted proteoglycan M-CSF. For example, the Stanley group has reported that a supplement of recombinant human M-CSF restored macrophage density in some tissues, such as liver or spleen, in CSF-deficient osteopetrotic mice but was unable to completely correct phenotypic defects. 33 Transgenic expression of membrane-bound CSF alone in these mice restored macrophage numbers in some tissues but did not rescue the loss of overall BM hematopoiesis, implicating the requirement of circulating M-CSF and proteoglycan M-CSF for BM hematopoiesis. In our MCKL0 mouse model, isolated BM had reduced M-CSF expression levels, presumably representative of membrane-bound M-CSF. When MCKL0-derived BM monocytes were stimulated with exogenous M-CSF (equivalent to secreted M-CSF), these cells differentiated to macrophages at a substantially slower rate than those isolated from Wt mice ( Figure 4A and 4B) , suggesting impaired M-CSF action in these LpL-deficient BM-derived monocytes. In fact, although LpL deficiency reduced BM M-CSF protein levels (ns), plasma M-CSF levels were similar between Wt and MCKL0 mice ( Figure III in the online-only Data Supplement). However, this lack of response may also be attributable to the reduced expression of M-CSF-R in both plasma (≈46% reduction; P<0.05) and BM cells ( Figure 3B ). Our preliminary studies show that the addition of exogenous LpL has little or no effects on BMMP cell differentiation (data not shown).
Transcriptional control of M-CSF-R has been extensively studied. 36 Master regulators of hematopoiesis, such as PU.1, C/EBPα, and NF-κB, control M-CSF-R expression. Inflammatory stimuli, such as endotoxin lipopolysaccharides, also induce M-CSF-R expression. However, transcriptional control of M-CSF is still not understood. Our data show that although exogenous LpL slightly increased M-CSF expression in MCKL0 BM myeloid precursor cells, there were no effects on M-CSF-R expression. Can increased cellular FA uptake stimulate M-CSF or M-CSF-R expression in vivo? It has been shown that peripheral monocyte overexpression of scavenger receptor type A and CD36, which enhance FA uptake, positively correlated with serum M-CSF levels in humans. 37 Therefore, when BM-derived myeloid precursor cells were treated with FAs, LA increased M-CSF expression. Thus, we suggest that LpL is important for M-CSF expression and required for M-CSF cellular interactions that cooperatively regulate monocyte differentiation to macrophages. However, the PPARs, which modulate lipid metabolism, cellular proliferation, and inflammatory responses, are widely expressed in many tissues, including in monocytes. Some FAs are direct ligands of PPARs 38 and important regulators of the expression of different PPARs. 39 Among the PPAR family, PPARγ is a negative regulator of M-CSF expression and production through transrepression of NF-κB. 40 PPARγ overexpression and treatment with its ligand, pioglitazone, decreased M-CSF gene expression and protein levels. 40 Our data show a consistent inverse relationship between PPARγ and M-CSF in BMMP cells; expression of M-CSF was downregulated while PPARγ was upregulated in MCKL0 mice. The addition of exogenous LpL and FA during BMMP differentiation increased PPARγ expression, which linked to a decrease in M-CSF expression in both Wt and MCKL0 mice. Our results are consistent with our earlier report 27 that MCKL0 mice had greater increases in expression of all PPARs in adipose tissues. It has been postulated that increased PPAR expression is induced by FAs through de novo lipogenesis. 27, 41 Because there are several positively charged binding motifs in LpL, we hypothesize that LpL anchors M-CSF by binding to the negatively charged residues on M-CSF. Studies from the Chait group show that macrophage-secreted M-CSF contains proteoglycan domains that can bind lipoproteins, such as LDL. 42 Acetylation or copper oxidation, which instill a net positive charge on LDL, resulted in a loss of M-CSF binding. 42 Based on the known ability of LpL to bind proteoglycans or LDL, we propose that LpL sequesters secreted circulating M-CSF at the cell surface and directs it to the M-CSF-R. In fact, our data on assessing whether exogenous LpL affects binding of M-CSF to its receptor by immunobinding assays show that M-CSF association with M-CSF-R decreased with increasing amounts of LpL in a solid-phase assay ( Figure IV in the online-only Data Supplement). In the absence of LpL, cellular association of M-CSF and M-CSF-R was significantly reduced. We have examined potential interacting factors that may affect M-CSF and M-CSF-R cellular interaction. The results indicate that M-CSF and M-CSF-R interaction is independent of LpL enzymatic activity. Consistent with the negative results from the immunobinding assay (data not shown), the addition of heparin has little or no effects on cell association of M-CSF and M-CSF-R in BM. However, cellular association of M-CSF and M-CSF-R was significantly reduced by NaClO 3 , which supports our hypothesis that LpL plays a role in bridging BM M-CSF proteoglycan to cells to catalyze the maturation of monocyte precursor or monocytes. We have previously reported that LpL bound to cell surface proteoglycans also bound LDL and facilitated LDL delivery to the LDL receptor. 43 Thus, similar to lipoproteins with anchoring functions, dimeric LpL might capture circulating M-CSF and increase its proximity to its receptor. Lack of LpL thus impairs the efficacy of M-CSF in stimulating myelopoiesis.
Decreased myelopoiesis induced by selective LpL deletion may be beneficial in some scenarios. The M-CSF/M-CSF-R signaling pathway is activated via the concerted action of other growth factors, such as GM-CSF/GM-CSF receptor. Although M-CSF expression is generally constant, GM-CSF expression increases in response to inflammatory stimuli. 44 Myeloid lineage populations display differential responses to M-CSF and GM-CSF albeit through unknown mechanisms. Interestingly, therapeutic antagonism of M-CSF and GM-CSF has been shown to ameliorate some inflammatory/autoimmune diseases, such as rheumatoid arthritis. 44 Atherosclerosis-prone disease models, such as apolipoprotein E knockout or LDL receptor (LDLR) knockout mice, display reduced atherosclerosis if macrophage-derived LpL is deleted. Apolipoprotein E knockout mice lacking LpL expression in macrophages after cre/loxP gene targeting had fewer atherosclerotic lesions than apolipoprotein E knockout with LpL-expressing macrophages after an HF, high-cholesterol diet. 13 Furthermore, Babaev et al 35 reported that irradiated LDLR −/− mice transplanted with fetal liver cells from LpLdeficient mice had smaller atherosclerotic lesions when compared with LDLR −/− mice reconstituted with LpL-expressing fetal liver cells. In our models, LpL deficiency not only reduced aortic macrophage levels but also reduced monocyte counts substantially. This makes it difficult to determine whether the reduction of atherosclerotic lesions observed in other studies is because of the lack of local LpL expression in arterial macrophagesor because of changes in altered BM and circulating leukocyte profiles.
LpL deficiency in the arterial wall is associated with fewer aortic macrophages even before atherosclerotic development.
Associations between LpL and aortic macrophages were examined through BM transplantation techniques that restore LpL to arterial cells, and the use of heparin, which mediates dissociation of LpL from the cell surface. We expect that heparin would further decrease aortic macrophages in LpL-deficient MCKL0 mice; however, the decreases would be difficult to detect because the levels of aortic macrophage in MCKL0 mice are already low. Heparin has been proposed to have antiinflammatory effects through its binding of various chemokines and cytokines, 45 prevention of proinflammatory mediators from interacting with their respective receptors, 46, 47 and modulation of TNFα and NF-κB activity. [48] [49] [50] Although the ability of heparin to induce LpL cellular dissociation is well established, the phenomenon of heparin-releasable macrophages in an acute setting has not been previously reported. The interaction of LpL with heparin, and likely several other molecules, is because of regions of positively charged heparin-binding motifs in LpL. Others have reported that heparin interferes with the adhesion of leukocytes to the endothelium through its binding to L-and P-selectin. 51 In contrast to other studies, we report an acute effect (≈10 minutes) of heparin on dissociation of arterial macrophages, and these effects on macrophage levels are correlated with macrophage-associated heparin-releasable LpL. Furthermore, we have established the close relationship between LpL and macrophages in atherogenesis in LDLR −/− mice in our earlier reports. 15 We speculate that the heparin would also affect arterial macrophage abundance in LDLR −/− mice. Nonetheless, the effects of heparin are complex in modulating function and activity of several proteins that are important in regulating inflammatory responses acutely and chronically. This is one limitation of the current studies.
In summary, LpL deficiency decreased circulating levels of total leukocytes, neutrophils, and total and inflammatory monocytes. These effects were partly mediated through CSFs and CSF-Rs, resulting in significant decreases in blood monocytes and BM-derived monocyte differentiation to macrophages. Loss of LpL in the arterial wall was also associated with reduced aortic macrophages in nonatherosclerotic mice. LpL can now be recognized as not only a key player in directing arterial lipid deposition but also as a potential regulator of blood and peripheral inflammatory responses.
